Heron Therapeutics, Inc. HRTX
0.37 USD 0.00 (-1.21%)
Nov 10, 2026, 1:16 PM EST
0.3401 Day range 0.414
0.26 52-week range 1.58
- YTD
- -71.84%
- 1 year
- -67.02%
News
seekingalpha.com Heron Therapeutics, Inc. (HRTX) M&A Call Transcript Heron Therapeutics, Inc. ( HRTX ) M&A Call November 9, 2026 4:30 PM EST Company Participants Joseph Todisco - CEO & Chairman of the Board of Directors Conference Call Participants Daniel Ferry -…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Heron Therapeutics Q3 EPS $(0.03), Inline, Sales $35.250M Miss $37.500M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.04) per share from the same…
benzinga.com CorMedix To Acquire Heron Therapeutics Assets For $145M Cash, Stock, And Potential Earn-Out Payments Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
benzinga.com Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement On September 23, 2026 (the "Effective Date"), Heron Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a multi-product Development and License Agreement (the "License- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
- benzinga.com Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses…
benzinga.com Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.
benzinga.com HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2 HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Heron Therapeutics To Appeal Delaware Court Ruling Invalidating Two CINVANTI Patents In Litigation With Azurity Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Earnings Scheduled For May 11, 2026 
benzinga.com Earnings Breakdown: Heron Therapeutics Q4 - benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com HC Wainwright & Co. Reiterates Buy on Heron Therapeutics, Maintains $6 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $6 price target.- benzinga.com Heron Therapeutics Reports Q4 Preliminary Net Revenue Of ~$40.5M, ~$154.9M For 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.Net…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Heron Therapeutics Includes APONVIE Injectable Emulsion In Guidelines For Postoperative Nausea, Vomiting Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly…
- benzinga.com UPDATE: Heron Therapeutics Q3 Adj. EPS $(0.04) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 166.67 percent. This is a 33.33 percent decrease over losses…
benzinga.com Heron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $156.482M Est Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million to $153.000 million-$163.000 million vs $156.482 million estimate.
benzinga.com Heron Therapeutics Q3 EPS $(0.10) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.01) by 900 percent. This is a 233.33 percent decrease over losses of…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Heron Therapeutics Adopts Section 382 Rights Plan To Protect Nols And Tax Attributes; Plan Approved By Board And Satisfies Covenant Under Note Agreement With Rubric Capital Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights…- benzinga.com Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $3 Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $3.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Heron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $158.538M Est Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million to $153.000 million-$163.000 million vs $158.538 million estimate.
- benzinga.com Heron Therapeutics Q2 EPS $(0.02) Misses $(0.01) Estimate, Sales $37.200M Miss $38.075M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 53.85 percent. This is a 66.67 percent increase over losses…
benzinga.com This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com HC Wainwright & Co. Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $6 HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy rating and announces Price Target of $6.
- benzinga.com Heron Therapeutics Affirms FY2025 Sales Guidance of $153.00M-$163.00M vs $157.27M Est Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.00 million-$163.00 million to $153.00 million-$163.00 million vs $157.27 million estimate.
- benzinga.com Heron Therapeutics Q1 EPS $0.01 Beats $(0.01) Estimate, Sales $38.90M Beat $37.42M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 150 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 6, 2025
- benzinga.com Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $4 price target.
- benzinga.com Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $4 price target.
- benzinga.com Heron Therapeutics Expects 2025 Sales Of $153M-$163M Versus Consensus Of $160.633M Financial Guidance for 2025 Item2025 Full-Year Guidance for Net Revenue and Adjusted EBITDA(in millions) Net Revenue$153.0 to$163.0Adjusted EBITDA$0.0to$8.0
- benzinga.com Heron Therapeutics Q4 2024 GAAP EPS $0.02 Beats $(0.03) Estimate, Sales $40.78M Beat $37.37M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.03) by 166.67 percent. This is a 128.57 percent increase over losses…
- benzinga.com Earnings Scheduled For February 27, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $4 price target.
- benzinga.com Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Earnings Scheduled For November 12, 2024
- benzinga.com Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session